Coverage
Orion has secured an exclusive license for an experimental cancer antibody from Abzena, the latest in a series of deals to strengthen its oncology pipeline following a recent clinical trial failure.
Finnish drugmaker Orion Corp. said Tuesday its experimental insomnia drug failed a mid-stage clinical trial, days after investment giant BlackRock Inc. cut its stake in the company.
Orion and its partner Bayer have secured European Union approval for an expanded use of their blockbuster prostate cancer drug, Nubeqa, the latest in a series of regulatory wins for the treatment.
Orion Corp. reported a 59% surge in second-quarter operating profit, driven by strong sales and royalty income from its blockbuster prostate cancer drug, Nubeqa.
Finnish drugmaker Orion on Wednesday raised its full-year 2025 forecast, citing stronger-than-expected product sales and royalty income.
A European Medicines Agency panel recommended expanding the use of a prostate cancer drug from Orion and its partner Bayer, moving the blockbuster treatment a step closer to a third approval in the region.
Filings
| Filing | Date |
|---|---|
| *CONVERSION OF A-SHARE INTO B-SHARE: ORI | 7 Jul 2003 |
| Orion centralises pharmaceutical manufac | 3 Jul 2003 |
| Oriola Oy to acquire the shares of KD Tu | 25 Jun 2003 |
| Orion focuses on pharmaceuticals | 25 Jun 2003 |
| Stalevo, Orion's new treatment for Parki | 13 Jun 2003 |
| Orion Pharma is focusing R&D | 5 Jun 2003 |
| Orion Pharma introduces negotiations wit | 27 May 2003 |
| Orion Group Interim Report 1-3/2003 | 13 May 2003 |
| Orion putting aside the New Venture proj | 12 May 2003 |
| B-warrants 1998 of Orion Corporation quo | 30 Apr 2003 |
| Profit warning: Orion estimates notably | 14 Apr 2003 |
| Information on the AGM of Orion Corporat | 28 Mar 2003 |